AtriCure to Present at Thomas Weisel Partners Healthcare Tailwinds 2005 Conference

AtriCure to Present at Thomas Weisel Partners Healthcare Tailwinds 2005 Conference

WEST CHESTER, Ohio, Sept. 2 /PRNewswire-FirstCall/ -- AtriCure, Inc. (NASDAQ:ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that management is scheduled to present at the Thomas Weisel Partners Healthcare Tailwinds 2005 Conference at The Four Seasons in Boston, MA on Wednesday, September 7, 2005 at 10:00 am ET.

A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCure's Web site at www.atricure.com . The recording will be available until October 7, 2005.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a rapid, irregular quivering of the upper chambers of the heart.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufactures and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Atricure
Thomas Etergino
Chief Financial Officer
513-755-4561
tetergino@atricure.com

The Ruth Group
Stephanie Carrington / Nick Laudico (investors)
(646) 536-7017 / 7030
scarrington@theruthgroup.comnlaudico@theruthgroup.com

Jason Rando (media)
(646) 536-7025
jrando@theruthgroup.com

Source: AtriCure, Inc.

CONTACT: Thomas Etergino, Chief Financial Officer, Atricure,
+1-513-755-4561, tetergino@atricure.com; or Stephanie Carrington,
+1-646-536-7017, scarrington@theruthgroup.com, or Nick Laudico (investors),
+1-646-536-7030, nlaudico@theruthgroup.com, or Jason Rando (media),
+1-646-536-7025, jrando@theruthgroup.com, all of The Ruth Group

Web site: http://www.atricure.com/

-------
Profile: jene29